Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

GlaxoSmithKline (NYSE:GSK) announced that Phase 3 clinical trial assessing asthma med Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) met both co-primary endpoints and all secondary endpoints.

• According to Bloomberg, Johnson & Johnson (NYSE:JNJ) has approached Actelion (OTCPK:ALIOY) about a potential takeover in a bid to boost its pharma business. Actelion's market valuation is currently close to $17 billion.
• AON (NYSE:AON) has agreed to acquire Admix, health and benefits brokerage and solutions firm. The company is based out of Brazil. The financial details of the deal have not been disclosed.


• Revive Therapeutics (OTCQB:RVVTF) reported its first quarter EPS at -C$0.01.
• Can-Fite Biopharma (NYSEMKT:CANF) reported its quarterly EPS at -$0.19. The company’s revenue for the quarter stood at $171 million.

• Jefferies reiterated its Buy rating for Bluebird Bio (NASDAQ:BLUE). Its price target is set at $80.